Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Public ClinicalTrials.gov record NCT03734029. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: * Cannot be removed by an operation * Has spread to other parts of the body
Study identification
- NCT ID
- NCT03734029
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 557 participants
Conditions and interventions
Conditions
Interventions
- Trastuzumab deruxtecan (DS-8201a) Drug
- Capecitabine Drug
- Eribulin Drug
- Gemcitabine Drug
- Paclitaxel Drug
- Nab-paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2018 (Actual)
- Primary completion
- Jan 11, 2022 (Actual)
- Completion
- May 19, 2026 (Actual)
- Last update posted
- Sep 28, 2026
2018 – 2026
United States locations
- U.S. sites
- 38
- U.S. states
- 21
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers - Chandler II | Chandler | Arizona | 85224 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Cancer Treatment Centers of America at Western Regional Medical Center | Goodyear | Arizona | 85338 | — |
| UCLA School of Medicine | Los Angeles | California | 90095 | — |
| Stanford Cancer Institute | Palo Alto | California | 94305 | — |
| Cancer Care Associates Medical Group, Inc. TORI | Redondo Beach | California | 90277 | — |
| University of California at San Francisco (PARENT) | San Francisco | California | 94158 | — |
| Eastern Connecticut Hematology/Oncology Assoc. | Norwich | Connecticut | 06360 | — |
| Christiana Care Health Services, Inc. | Newark | Delaware | 19713 | — |
| Sylvester Comprehensive Cancer Center - Deerfield Beach | Boca Raton | Florida | 33426 | — |
| Florida Cancer Specialists (South Region) | Fort Myers | Florida | 33916 | — |
| Memorial Healthcare System MRH Cancer Center | Hollywood | Florida | 33021 | — |
| Orlando Health, Inc. | Orlando | Florida | 32806 | — |
| Moffitt Cancer Center -Tampa | Tampa | Florida | 33139 | — |
| Cancer Treatment Centers of America-Georgia | Newnan | Georgia | 30263 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Cancer Treatment Centers of America | Zion | Illinois | 60099 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Touro Infirmary | New Orleans | Louisiana | 70115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Saint Luke's Hospital of Kansas City | Kansas City | Missouri | 64111 | — |
| Saint Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| New York University Medical Center | New York | New York | 10016 | — |
| Memorial Sloan Kettering Hospital | New York | New York | 10065 | — |
| Weill Cornell Medicine Breast Center | New York | New York | 10065 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| University of Pittsburgh Medical Center Health System | Pittsburgh | Pennsylvania | 15219 | — |
| St Francis Hospital | Greenville | South Carolina | 29601 | — |
| Brig Center for Cancer Care and Survivorship | Knoxville | Tennessee | 37909 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| Tennessee Oncology - Skyline Satellite | Nashville | Tennessee | 37201 | — |
| BloomTrials Clinical Research, LLC | Dallas | Texas | 75234 | — |
| The Methodist Hospital Research Institute | Houston | Texas | 77030 | — |
| University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 170 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03734029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03734029 live on ClinicalTrials.gov.